Invokana, Farxiga New Safety Warning May Give Jardiance Market Edge
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA strengthens warning about risk of acute kidney injury for two SGLT2 inhibitors but not Jardiance, the only diabetes drug with data on cardiovascular benefit.